HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

HAEMATO AG / Key word(s): Regulatory Admission/Alliance

HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

25-Oct-2021 / 10:21 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

Seoul and Schönefeld, 25th October 2021 – HAEMATO PHARM GmbH (“HAEMATO”), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1) is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons BioPharma Co., Ltd. (“Huons BioPharma”), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have concluded an exclusive licence and supply agreement for the product known in Korea under the brand names LIZTOX(R) and HUTOX(R). By distributing a botulinum toxin product under its own brand, HAEMATO is further expanding its “Lifestyle & Aesthetics” division. This will also ensure the long-term supply of the parent company, M1 Kliniken AG (ISIN: DE000A0STSQ8), one of the leading providers of beauty treatments in Europe, with an attractively priced botulinum toxin product. In addition, the product is to be marketed in all European countries. For the approval in Europe, both sides are planning a European marketing authorization procedure, which also includes clinical trials. The parties have agreed not to disclose detailed financial terms of the agreement.

About HAEMATO:
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced specialty pharmaceuticals (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of “Lifestyle & Aesthetics”. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at www.haemato.de

About Huons BioPharma:
Huons BioPharma Co., Ltd. was spun off from the holding company, Huons Global Co., Ltd. in April 2021 to expand the botulinum toxin product business, enter into global market and focus on the development of new biopharmaceuticals. The company aims to improve the quality of life by developing biopharmaceuticals for intractable diseases as well as to advance the international roll-out of HUTOX(R). Huons BioPharma future objectives are the expansion of indications as well as the further development of next-generation botulinum toxin through continuous R&D investment.

About LIZTOX(R) / HUTOX(R)
LIZTOX(R) or HUTOX(R) , is an injectable botulinum toxin type A indicated for the treatment and “smoothing” of moderate to severe wrinkles in the facial area, has been registered and marketed in Korea and several other Asian countries. Since its launch in Korea in the second quarter of 2020, LIZTOX(R) managed to strengthen its position among leading botulinum toxin products in Korea.

Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag


25-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this